Neutralizing antibodies to interferon β-1b are not associated with disease worsening in multiple sclerosis

Journal of International Medical Research

Volumn 35, Issue 2, 2007, Pages 173-187

  Goodin, D S ^a   Hurwitz, B ^b   Noronha, A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Clinical efficacy; Immunomodulatory drugs; Interferon beta; Multiple sclerosis; Neutralizing antibodies; Radiological impact

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; EUROPE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NORTH AMERICA;

EID: 34147167957     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000703500202     Document Type: Article

References (43)

1. Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R: Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000; 48: 95-100.
2. Hemmer B, Stuve O, Kieseier B, Schellekens H, Hartung HP: Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 2005; 4: 403-412.
3. IFNβ Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing - remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
4. IFNβ Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-894.
5. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al and the Multiple Sclerosis Collaborative Research Group (MSCRG): Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-294.
6. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, et al for the CHAMPS Study Group: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
7. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
8. Goodin DS, Frohman EM. Garmany GP, Jr, Halper J, Likosky WH, Lublin FD, et al: Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-178.
9. Francis GS, Rice GP, Alsop JC and the PRISMS Study Group: Interferon beta-1a in MS: results following development of neutralizing anti-bodies in PRISMS. Neurology 2005; 65: 48-55.
10. Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, et al and the European Interferon Beta-1a IM Dose-Comparison Study Investigators: Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-47.
11. Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD et al and the IFNB Multiple Sclerosis Study Group: Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 126-138.
12. Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli C, et al for the European Study Group in Interferon Beta-1b in Secondary Progressive MS: Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003; 60: 37-43.
13. Rio J, Tintore M, Tellez N, Nos C, Galan I, Montalban X: [Long-term effect of neutralizing antibodies to interferor beta-1 b in patients with multiple sclerosis.] Med Clin (Barc) 2005; 124: 140-141 (in Spanish).
14. Panitch H. Goodin DS, Francis G, Chang P. Coyle PK, O'Connor P, et al: Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002; 59: 1496-1506.
15. Durelli L, Verdun E, Barbero P. Bergli M, Versino E, Grezzi A, et al: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453-1460.
16. Panitch H. Goodin DS. Francis G. Chang P, Coyle P, O'Connor P et al, the EVIDENCE Study Group, and the UBC MS/MRI Research Group: Benefits of hih-dose, high-frequency interferon beta-1a in relapsin MS are sustained to 16 months: final comparative results of the EVIDENCE trial, J Neurol Sci 2005; 238: 67-74.
17. Rice GP, Paszner B, Oger J, Lesaux J, Paty D, Ebers G: The evolution of neutralizing anti-bodies in multiple sclerosis patients treated with interferon β-1b. Neurology 1999; 52: 1277-1279.
18. Sorensen PS, Ross C. Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, et al the Danish Multiple Sclerosis Study Group: Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-1191.
19. The North American Study Group on Interferon beta-1a in Secondary Progressive MS: Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004; 63: 1788-1795.
20. Herndon RM, Rudick RA, Munschauer III FE, Moss MK, Salazar AM, Coats ME. et al: Eight-year immunogenicity and safety of interferon beta-1a-Avonex® treatment in patients with multiple sclerosis. Mult Scler 2005; 11: 409-419.
21. Sorensen PS, Koch-Henriksen N, Ross C, Clemmesen KM, Bendtzen K: Appearance und disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33-39.
22. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
23. The IFNB Multiple Sclerosis Study Group, the UBC MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-1285.
24. European Study Group on Interferon β-1b in Secondary Progressive MS: Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancel 1998; 352: 1491-1497.
25. PRISMS Study Group, the UBC MS/MRI Analysis Group: PRISMS-4: Long-term efficacy of interferon-beta-1a in relopsing MS. Neurology 2001; 56: 1628-1636.
26. SPECTRIMS Study Group: Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496-1504.
27. Rudick RA, Simonian NA, Alum JA, Campion M, Scaramucci JO, Jones W, et al: Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1266-1272.
28. Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B, et al: Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology 2004; 62: 719-725.
29. The IFNB Multiple Sclerosis Study Group: Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b. Neurology 1996; 47: 889-894.
30. Clanet M, Radue EW, Kappos L, Hartung HP, Hohlfeld R, Sandberg-Wollheim M, et al, the European IFN beta-1a (Avonex) Dose-Comparison Study Investigators: A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59: 1507-1517.
31. Barbero P, Bergui M, Versino E, Ricci A, Zhong JJ, Ferrero B, et al, the INCOMIN Trial Study Group: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: Analysis of MRI responses to treatment and correlation with NAb. Mult Scler 2006; 12: 72-76.
32. Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, et al: Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis. Neurology 2004; 62: 2031-2037.
33. Perini P, Calabrese M: The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004; 251: 305-309.
34. Gilli F, Sala F, Hoffmann F, Marnetto F, Caldano M, Kappos L, et al: Anti-interferon beta neutralizing activity is not entirely mediated by antibodies. Mult Scler 2005; 11(Suppl 1): S2-S3.
35. Files JG, Gray JL, Do LT, Foley WP, Gabe JD, Nestaas E, et al: A novel sensitive and selective bioassay for human type I interferons. J Interferon Cytokine Res 1998; 18: 1019-1024.
36. McKay F, Schibeci S, Heard R, Stewart G, Booth D: Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort. J Immunol Methods 2005; 310: 20-29.
37. Grossberg SE, Kawade Y, Kohase M, Klein JP: The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001; 21: 743-755.
38. Noronha AB, Antel JP, Roos RP, Medof ME: Circulating immune complexes in neurologic disease. Neurology 1981; 31: 1402-1407.
39. Noronha A, Toscas A, Jensen MA: Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 1990; 27: 207-210.
40. Noronha A, Toscas A, Arnason BG, Jensen MA: IFN-beta augments in vivo suppressor function in MS. Neurology 1994; 44(Suppl 2): A212.
41. Miller A, Lider O, Roberts AB, Sporn MB, Weiner HL: Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci USA 1992; 89: 421-425.
42. Brenner T, Arnon R, Sela M, Abramsky O. Meiner Z, Riven-Kreitman R, et al: Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone®. J Neuroimmunol 2001; 115: 152-160.
43. Haas J, Maas-Enriquez M, Hartung HP: Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years. Mult Scler 2005; 11: 562-567.